IDEAYA Biosciences announces first patient dosed in Phase 1 IDE849 and IDE161 combination study
IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.










